The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I don’t think that includes ff+ as we already have stock ,so maybe £145k on top
Correct Gixer, some only read what they want to see. Lets see full year results. Usual and new suspects putting there doom and gloom. Also raising is maybe not will have to
If sales are lower than wages, one has to ask when will they need funding to keep paying the wages?
£280k for first six months with another £155k in the pipeline. Its only September, we have another 6 months of the financial year to go. Think you are being a bit mean at £509k :)
Not sure you have those figures right.
Firstly, I would think that DSM would have made sure that their customers bought from them before they handed over, which would have a chilling effect for a while. Then, if turnover for the half year was 280k, the second half should deliver that and more. Having sales of 155k on the books at the start of the second half of the year, there's a good prospect that the second half will beat the first by some margin.
Setting up a despatch hub in Ireland is another cost, but, if it avoids tariffs (debatable), it could be self funding.
I've warned a few times that we shouldn't expect much from this report, only the full year to 24 will give a better guide.
I'm not happy that this view has been born out.
Terrible results. £354k in 9 months (74+280) with another £155k in the pipeline this year. So that will be about £509k (74+280+155) income in a full calendar year, with a good portion of that going to DSM.
That means BH order will potentially be multiple of not much.
This company just can't make a profit after 14 years of trading! At least it's clear that another fundraise is imminent.
Pretty underwhelming to be honest, with total revenue for FF ( from DSM and direct sales ) down, but at least we've got some flesh on the bones wrt sales of FF in H1 ( Apr to Sept ) for this FY for which we're still expected to be loss making.
I'd hoped our current cashflow would have been closer to break even than recent sales suggest. The need to fund raise is, as expected, still there but can't, I'm assuming, be very far away now.
BB
?
Ah ok. I wonder how the patent application is doing for that one. DSM has preferential access to the use this patent but i wonder how binding this partnership is remembering that it was based on DSM's study?
Gixer sorry I was referring to the gut microbiome which DSM are fastracking to market apparently ! Anyway let’s hope some answers are in the report tomorrow and as alfista has said don’t expect any news on funding as it has been a great tool to keep a cap on the sp for a year now , I might be a bit cynical but it has been frustrating .
Sphinx, the new function claim was only submitted on the 29th of August (one month ago) once SAMR finally officially released the "Implementation Rules for New Functions and Product Technology Evaluation of Health Foods" on 28th August.
The Technical Specifications for Testing and Evaluation of Health Food (2003 Version) was abolished in July 2018 so we can hardly blame PXS or By-Health for the delay. The good thing was By-Health were ready and waiting.
We know what we're waiting for.
The link with ByHealth, with their chief scientist having started his training with Provexis is the significant part of the story. All of the years developing Fruitflow, all of the added health function, but still they revert to the original one for Blue Cap approval. They have massive promotional capabilities, and have been preparing their PR offerings for ages. This is where the big numbers (and sp) is achievable, the extra revenues could unlock to door to proper promotion in other markets.
In that respect, we still have to wait. For the new trading pattern, we can hope to start gaining some insights.
I’m not expecting anything that will move the sp , more cut & paste and hopeful link ups with mysterious 3rd parties I expect . The “ New” function claim will be talked about even though it’s 15 months old now . Nothing happens with any pace at pxs I’m afraid . I hold in hope though!
Like many AIM CEO's Ian Ford has earned many millions by "running" a loss-making outfit. It really is a gravy train isn't it? 2009 to 2023 and yet to make a profit! It never really lived up to the potential and probably never will. Good product though.
Although there is no requirement to publish them I hope we get some (unofficial) figures for March to September.
Will we break even?
- no trade in jan, possibly part of Feb too
- loss due to lockdowns
- majority of customers transferred, not all.
We should see a some revenue increase, but not sure we’ll break even for year 22/23. Only 1 day until we find out.
Will it be 14 years in row 'No profit? OR being positive:Loss decreasing x
What test results are we waiting on?
The results will be I reckon disappointing which is why they got the positive news out 1st to lift the SP , this hasn't worked however people buying under 0.6p now. I think it will be going lower. Test results a long way off. GLA
By Health haven't got Blue Cap approval yet, so the orders that could be multiples of any prior order are still pending as far as we can tell.
Therefore, mu expectations are modest. Will the cash requirement be conclusively addressed? Doubt it, I think it will still be the sword of Damocles' over the sp.
Not that I know, only management do.
I'm just teasing, I don't think anyone expects anything other than the usual "multiples of existing sales" guff. I'm actually tempted to buy another 500k at the current price though. Any whiff of good news could easily send this over a penny IMHO.
The first sales were not until some time in Feb?. So we will only get some Feb and all March on the new structure. Then I am not confident that they will split that out in the results and if they do it will be a bit meaningless. Hopefully we get some good news, but I think December is where we can start to make sense of their forecasts. I think the Friday RNS will be more of the same, but hope I am wrong.
Come on Dr_H, stop kicking the can down the road. c. £6m profit from the remaining stock you said, surely that'll be £1.5 million in the first quarter then? No? No, thought not, more of the same, as you now (like me) suspect. You never know though...